Abiraterone in combination with prednisone is approved for use in men with metastatic castration-resistant prostate cancer and also in newly diagnosed high risk metastatic hormone sensitive prostate cancer, with phase III studies demonstrating an overall survival EN(OS) benefit and an acceptable toxicity profile.22, –24 Phase II trials of abiraterone in ER positive breast cancer and AR positive triple-negative breast cancer have been reported minimal activity.25,26 To date, there have been no studies of abiraterone in EOC. The gene discussed is AR; the disease is prostate carcinoma.